English
About Prostatype Genomics
The company Prostatype Genomics AB was founded in 2007 as a spin off from Cancer Center Karolinska (Karolinska Institutet, Stockholm, Sweden).To date, 15 years of research work in the area of prostate cancer genomics has resulted in the development of a market-ready product, providing decision support for treatment selection of prostate cancer patients: The Prostatype® Test System. The system is based on a gene expression test, which measures the expression of three carefully selected embryonic stem cell genes in prostate cancer core needle biopsies. In conjunction with currently used clinical parameters, the PrTS predicts overall survival in relation to treatment.
Vision & Mission
The Prostatype® Test System – a new gene test for prostate cancer patients
Our vision is that doctors and patients, confronted with diagnosed prostate cancer, have full confidence in their treatment decisions.
Prostatype Genomics mission is to make a difference in prostate cancer patients’ lives through the discovery and commercialization of transformative tests to guide treatment decisions. We can thereby increase quality of life and peace-of-mind for patients and simultaneously reduce health care costs. Prostatype Genomics will achieve this by making PrTS the global test system of choice for newly diagnosed prostate cancer patients.
How it works
The Prostatype® Test System is a new gene test that provides:
• Prognosis of survival
• Decision support for various treatment options
The Prostatype® Test System combines gene expression information with the currently used clinical parameters (PSA, Gleason Score, Tumour Stage, and age). Based on a unique database containing authentic information from 600 historic prostate cancer patients, the Prostatype® Test System provides decision support for patients and doctors when making a treatment decision. This reduces the risk of over- or undertreatment and can postpone repeated biopsies.
Results
Based on the genetic profile and clinical data of the patient, the P-Score is estimated. The P-Score indicates the aggressiveness of the tumour. The prostate cancer-specific mortality risk at 10 years for a patient with a low P-Score (green) is below 3.4%, for an intermediate P-Score (yellow) it is below 10.8%. In addition, the software identifies the three most similar reference patients from an authentic historic database. The treatment, survival time and cause of death of the reference patients is displayed and serve as a decision support when choosing the optimal treatment for the patient.
Substantial commercial opportunities for Prostatype Genomics in a global market
• By providing new and personalized information, Prostatype Genomics is actively involved in the radical transformation of prostate cancer healthcare with its Prostatype® Test System (PrTS)
• Significant market opportunity in prostate cancer market segment: 630 MEUR annually
• Studies indicate over‐ and undertreatment of 7 out of 10 prostate cancer patients
• Ready for market: CE‐approved, IP protected and ISO 13485:2012 certified
• Clinical studies with early adopters validate PrTS – concluded and ongoing studies
• First commercial installation of PrTS expected second half of 2016
• Highly scalable business model with recurring sales
• Prostatype Genomics is improving patients’ quality of life while reducing healthcare costs:
• combining genetic testing using stem cell gene signatures,
• with advanced data analysis (unique proprietary patient database and algorithm),
• evolution towards personalized medicine in prostate cancer healthcare,
• Prostatype Genomics Medicals has and will conduct all its activities based on good ethics for the patients.
For more information about Prostatype Genomics and the Prostatype® Test System (PrTS), please visit www.prostatypegenomics.com
The company Prostatype Genomics AB was founded in 2007 as a spin off from Cancer Center Karolinska (Karolinska Institutet, Stockholm, Sweden).To date, 15 years of research work in the area of prostate cancer genomics has resulted in the development of a market-ready product, providing decision support for treatment selection of prostate cancer patients: The Prostatype® Test System. The system is based on a gene expression test, which measures the expression of three carefully selected embryonic stem cell genes in prostate cancer core needle biopsies. In conjunction with currently used clinical parameters, the PrTS predicts overall survival in relation to treatment.
Vision & Mission
The Prostatype® Test System – a new gene test for prostate cancer patients
Our vision is that doctors and patients, confronted with diagnosed prostate cancer, have full confidence in their treatment decisions.
Prostatype Genomics mission is to make a difference in prostate cancer patients’ lives through the discovery and commercialization of transformative tests to guide treatment decisions. We can thereby increase quality of life and peace-of-mind for patients and simultaneously reduce health care costs. Prostatype Genomics will achieve this by making PrTS the global test system of choice for newly diagnosed prostate cancer patients.
How it works
The Prostatype® Test System is a new gene test that provides:
• Prognosis of survival
• Decision support for various treatment options
The Prostatype® Test System combines gene expression information with the currently used clinical parameters (PSA, Gleason Score, Tumour Stage, and age). Based on a unique database containing authentic information from 600 historic prostate cancer patients, the Prostatype® Test System provides decision support for patients and doctors when making a treatment decision. This reduces the risk of over- or undertreatment and can postpone repeated biopsies.
Results
Based on the genetic profile and clinical data of the patient, the P-Score is estimated. The P-Score indicates the aggressiveness of the tumour. The prostate cancer-specific mortality risk at 10 years for a patient with a low P-Score (green) is below 3.4%, for an intermediate P-Score (yellow) it is below 10.8%. In addition, the software identifies the three most similar reference patients from an authentic historic database. The treatment, survival time and cause of death of the reference patients is displayed and serve as a decision support when choosing the optimal treatment for the patient.
Substantial commercial opportunities for Prostatype Genomics in a global market
• By providing new and personalized information, Prostatype Genomics is actively involved in the radical transformation of prostate cancer healthcare with its Prostatype® Test System (PrTS)
• Significant market opportunity in prostate cancer market segment: 630 MEUR annually
• Studies indicate over‐ and undertreatment of 7 out of 10 prostate cancer patients
• Ready for market: CE‐approved, IP protected and ISO 13485:2012 certified
• Clinical studies with early adopters validate PrTS – concluded and ongoing studies
• First commercial installation of PrTS expected second half of 2016
• Highly scalable business model with recurring sales
• Prostatype Genomics is improving patients’ quality of life while reducing healthcare costs:
• combining genetic testing using stem cell gene signatures,
• with advanced data analysis (unique proprietary patient database and algorithm),
• evolution towards personalized medicine in prostate cancer healthcare,
• Prostatype Genomics Medicals has and will conduct all its activities based on good ethics for the patients.
For more information about Prostatype Genomics and the Prostatype® Test System (PrTS), please visit www.prostatypegenomics.com
Sales and Product Marketing Manager
to innovative Life Science company with high market potential
Job Title: Sales and Product Marketing Manager
Reports to: VP Commercial Operations
The Position
Prostatype Genomics is currently in an exciting phase of development. The company has a unique product, the Prostatype® Test System (PrTS) to be launched globally.
Prostatype Genomics mission is to make a difference in prostate cancer patients’ lives through the discovery and commercialization of transformative tests to guide treatment decisions. We can thereby increase quality of life and peace-of-mind for patients and simultaneously reduce health care costs. Prostatype Genomics will achieve this by making PrTS the global test system of choice for newly diagnosed prostate cancer patients.
So far, the company has primarily focused on R&D to develop the PrTS and receive the regulatory approvals and certifications.
With the PrTS ready to market, Prostatype Genomics is coming into a new phase with focus on the global launch of PrTS. This means adding new professional resources and functions to reach the company objectives.
Prostatype Genomics was successfully listed on Nasdaq Stockholm First North during autumn 2020.
The team currently consist of around 5 people with different specialties and competencies, as well as many consultants connected to the company. Prostatype Genomics will grow substantially the coming months recruiting to several new key positions.
The Sales & Product Marketing (S&PM) Manager is responsible for making the products “fly-off the shelf.” This person is the product evangelist and play an integral role in organizing product launches and ongoing commercialization activities. This role is responsible for growing the revenue within the Nordic Territory by contacting and contracting new clients/customers.
The S&PM Manager collaborates with the commercial management team to develop innovative programs that drive demand. An attention to detail, an eye for quality and an ability to grasp and present our product’s value proposition in a way that resonates and clearly articulates how we solve our buyers’ problems, are critical to our success. In addition to the Prostatype Genomics management team, the S&PM Manager collaborates with the product managers of our sales channel partners; it’s a balancing act that requires strong diplomatic skills, including knowing when to push back and when to dive in.
Opportunities with the role and company
• The opportunity to work for Prostatype Genomics, a growing and innovative company that is in a very interesting phase of development, launching a new groundbreaking diagnostic solution, PrTS for Prostate cancer patients, healthcare, and society
• Be part of a company that develops a very attractive solution that has the opportunity to really change the life for many patients with Prostate cancer
• Become a leading player within Prostatype Genomics with the opportunity to influence the strategy, way of working, company development and key decisions, and to contribute to Prostatype Genomics future growth and development
• To work in a small company with a dynamic culture, freedom of action, a nice atmosphere and collaborative environment
• Work in values-based company, deeply rooted in science and innovation to transform new ideas and discoveries into solutions for patients with Prostate cancer
• Be part of a very competent and experienced team with high energy, all very committed to develop the company and the technology
• Have the opportunity to get in on the “ground floor” of the organization, when there is a chance to shape the future and really “leave your mark”
• Good possibilities to personal and professional development
Contact
For more information and questions about the Sales and Product Marketing Manager position, please contact Sven-Erik Matsson, Senior Recruitment Consultant at PeakSearch.
Contact details:
Sven-Erik Matsson, sven-erik.matsson@peaksearch.se Tel: 070-332 41 43
Reports to: VP Commercial Operations
The Position
Prostatype Genomics is currently in an exciting phase of development. The company has a unique product, the Prostatype® Test System (PrTS) to be launched globally.
Prostatype Genomics mission is to make a difference in prostate cancer patients’ lives through the discovery and commercialization of transformative tests to guide treatment decisions. We can thereby increase quality of life and peace-of-mind for patients and simultaneously reduce health care costs. Prostatype Genomics will achieve this by making PrTS the global test system of choice for newly diagnosed prostate cancer patients.
So far, the company has primarily focused on R&D to develop the PrTS and receive the regulatory approvals and certifications.
With the PrTS ready to market, Prostatype Genomics is coming into a new phase with focus on the global launch of PrTS. This means adding new professional resources and functions to reach the company objectives.
Prostatype Genomics was successfully listed on Nasdaq Stockholm First North during autumn 2020.
The team currently consist of around 5 people with different specialties and competencies, as well as many consultants connected to the company. Prostatype Genomics will grow substantially the coming months recruiting to several new key positions.
The Sales & Product Marketing (S&PM) Manager is responsible for making the products “fly-off the shelf.” This person is the product evangelist and play an integral role in organizing product launches and ongoing commercialization activities. This role is responsible for growing the revenue within the Nordic Territory by contacting and contracting new clients/customers.
The S&PM Manager collaborates with the commercial management team to develop innovative programs that drive demand. An attention to detail, an eye for quality and an ability to grasp and present our product’s value proposition in a way that resonates and clearly articulates how we solve our buyers’ problems, are critical to our success. In addition to the Prostatype Genomics management team, the S&PM Manager collaborates with the product managers of our sales channel partners; it’s a balancing act that requires strong diplomatic skills, including knowing when to push back and when to dive in.
Opportunities with the role and company
• The opportunity to work for Prostatype Genomics, a growing and innovative company that is in a very interesting phase of development, launching a new groundbreaking diagnostic solution, PrTS for Prostate cancer patients, healthcare, and society
• Be part of a company that develops a very attractive solution that has the opportunity to really change the life for many patients with Prostate cancer
• Become a leading player within Prostatype Genomics with the opportunity to influence the strategy, way of working, company development and key decisions, and to contribute to Prostatype Genomics future growth and development
• To work in a small company with a dynamic culture, freedom of action, a nice atmosphere and collaborative environment
• Work in values-based company, deeply rooted in science and innovation to transform new ideas and discoveries into solutions for patients with Prostate cancer
• Be part of a very competent and experienced team with high energy, all very committed to develop the company and the technology
• Have the opportunity to get in on the “ground floor” of the organization, when there is a chance to shape the future and really “leave your mark”
• Good possibilities to personal and professional development
Contact
For more information and questions about the Sales and Product Marketing Manager position, please contact Sven-Erik Matsson, Senior Recruitment Consultant at PeakSearch.
Contact details:
Sven-Erik Matsson, sven-erik.matsson@peaksearch.se Tel: 070-332 41 43